The Hindu Business Line : Biological E, Intercell in pact for encephalitis vaccine

BIOLOGICAL E. Ltd (BE), the Hyderabad-based leading vaccines manufacturer, has entered into a strategic alliance with the US-based pharmaceutical major Intercell AG for the development, manufacture and sale of the latter's Japanese Encephalitis vaccine in Asia. Under the terms of the agreement, Biological E. would manufacture the product in India for the Asian endemic market.

Intercell AG was planning to market the product on its own in the US, Europe and Australia targeting the travellers' and armed forces' market to replace current suboptimal vaccines produced on mouse brain. The Chief Operating Officer of Intercell AG, Mr Gerd Zettlmeissl, said, "This agreement with a leading Asian vaccine manufacturer leverages the commercialisation of our Japanese Encephalitis vaccine and will be another step in our efforts to continue to develop and commercialise our broad portfolio of vaccine candidates and technologies."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Trust property: Arguments against Lodha, others end

Mallya gets closer to SWC, likely to revise offer — Komal Chhabria not tobid at `any price'

Su-Raj Diamond picks up 49% stake in Forever Precious

TIIC unlikely to sell stake in Malco

Max Healthcare to raise Rs 75 cr thru equity placement

Biological E, Intercell in pact for encephalitis vaccine

Reliance Energy seeks pact with electrical contractors

Payroll giving programme to help the underprivileged in Mumbai

AP CM writes to Centre as BHPV revival hangs fire

Videocon Ind to raise Rs 2,000 cr for oil exploration

March belies hopes so far; Maruti to halt production for two days

Ford sales set to cross Rs 1,000-cr mark

`PSUs will do well to adopt quality programmes'